IP Verse

Dry Powder Medicament Inhaler - EP4188491

The patent EP4188491 was granted to Norton Waterford on May 8, 2024. The application was originally filed on Jun 22, 2022 under application number EP22736235A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4188491

NORTON WATERFORD
Application Number
EP22736235A
Filing Date
Jun 22, 2022
Status
Granted And Under Opposition
Apr 5, 2024
Grant Date
May 8, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KILBURN & STRODEFeb 8, 2025KILBURN & STRODEADMISSIBLE

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONGB2242134
DESCRIPTIONWO2007012871
INTERNATIONAL-SEARCH-REPORTUS2020324064
INTERNATIONAL-SEARCH-REPORTWO2010135253
INTERNATIONAL-SEARCH-REPORTWO2011129785
INTERNATIONAL-SEARCH-REPORTWO2018094392
INTERNATIONAL-SEARCH-REPORTWO2020025977
OPPOSITIONUS2002066451
OPPOSITIONUS2005154491
OPPOSITIONUS2009314291
OPPOSITIONUS2020324064
OPPOSITIONWO2005014089
OPPOSITIONWO2006018261
OPPOSITIONWO2007012871
OPPOSITIONWO2010135253
OPPOSITIONWO2011067212
OPPOSITIONWO2011129785
OPPOSITIONWO2018094392
OPPOSITIONWO2020025977
OPPOSITIONWO2021195353

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "ADVAIR DISKUS (fluticasone propionate and salmeterol inhalation powder), for oral inhalation use", HIGHLIGHTS OF PRESCRIBING INFORMATION, FDA, (20190101), pages 1 - 63, HIGHLIGHTS OF PRESCRIBING INFORMATION, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021077s061lbl.pdf, XP093259957-
OPPOSITION- Anonymous, "Label for Wixela (fluticasone propionate and salmeterol inhalation powder, USP)", Drugs at FDA: Label for Wixela, FDA, (20190101), pages 1 - 63, Drugs at FDA: Label for Wixela, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208891Orig1s000lbl.pdf, XP093259972-
OPPOSITION- Boston Children's Hospital, "How To Use An Ellipta Inhaler | Boston Children's Hospital", (20190604), URL: https://www.youtube.com/watch?v=E6X0zW4HQLk, XP093259969-
OPPOSITION- Copd Foundation, "Wixela Inhaler", (20190502), URL: https://www.youtube.com/watch?v=n-AdzaPEpxE, XP093259976-
OPPOSITION- D14a: INTERNET ARCHIVE WAYBACK MACHINE FOR D14 (US Food and Drug Administration (FDA) label for ELLIPTA inhaler (January 2019 revision)) https://web.archive.org/web/20210329042913/https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204275s017lbl.pdf)-
OPPOSITION- D15a - INTERNET ARCHIVE WAYBACK MACHINE FOR D15 : US Food and Drug Administration (FDA) label for DISKUS inhaler (January 2019 revision) https://web.archive.org/web/20200901125555/https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021077s061lbl.pdf-
OPPOSITION- D17a - DOCUMENT SHOWING PRINT OUT OF D17 YOUTUBE WEBSITE (PAGE 1), SCREENSHOTS FROM THE VIDEO OF D17 (PAGES 2 AND 3), AND INTERNET ARCHIVE WAYBACK MACHINE FOR D17 (PAGE 4)-
OPPOSITION- D18a - DOCUMENT CONTAINING PHOTOGRAPHS OF A DISKUS INHALER PRODUCT-
OPPOSITION- D20a - INTERNET ARCHIVE WAYBACK MACHINE FOR D20: Label for Wixela (fluticasone propionate and salmeterol inhalation powder, USP) (https://web.archive.org/web/20250306102811/https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208891Orig1s000lbl.pdf)-
OPPOSITION- D22a - DOCUMENT SHOWING PRINT OUT OF D22 YOUTUBE WEBSITE (PAGE 1), SCREENSHOTS FROM THE VIDEO OF D22 (PAGES 2 AND 3), AND INTERNET ARCHIVE WAYBACK MACHINE FOR D22 (PAGE 4)-
OPPOSITION- Fda, "BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder)", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20190101), pages 1 - 59, HIGHLIGHTS OF PRESCRIBING INFORMATION, XP093192241-
OPPOSITION- Gsk, "GSK - Four years ago, we first launched the first Ellipta...", Facebook, Facebook.com, (20171002), pages 1 - 2, Facebook, URL: https://www.facebook.com/GSK/posts/pfbid0vL99v1aRcBT6rN7u1WATSVEsDgZbtLk2ySH7h42Jb4r7owaXhcj8CgUYV8Y97KcAl/, XP093259967-
OPPOSITION- Waller Christine, Melissa Trombetta, "Mylan Announces FDA Approval of Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder)", Mylan News, Mylan N.V., (20190131), pages 1 - 4, Mylan News, URL: https://investor.mylan.com/news-releases/news-release-details/mylan-announces-fda-approval-wixelatm-inhubtm-fluticasone, XP093259948-
OPPOSITION- Waller Christine, Melissa Trombetta, "Mylan Announces FDA Approval of Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) | ", Mylan News, Mylan N.V., (20201001), pages 1 - 1, Mylan News, URL: https://web.archive.org/web/20201001043209/https://investor.mylan.com/news-releases/news-release-details/mylan-announces-fda-approval-wixelatm-inhubtm-fluticasone, XP093259951-
OPPOSITION- H. Chrystyn, "The DiskusTM: a review of its position among dry powder inhaler devices", INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, MEDICON INTERNATIONAL, ESHER, GB, GB , (20070510), vol. 61, no. 6, doi:10.1111/j.1742-1241.2007.01382.x, ISSN 1368-5031, pages 1022 - 1036, XP072059952

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents